Provided by Tiger Fintech (Singapore) Pte. Ltd.

NeuroPace Inc.

10.41
-0.1900-1.79%
Post-market: 10.410.00000.00%19:21 EDT
Volume:273.09K
Turnover:2.87M
Market Cap:341.43M
PE:-12.56
High:10.73
Open:10.60
Low:10.38
Close:10.60
Loading ...

BRIEF-NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study

Reuters
·
27 May

Neuropace Shares Fall 10.9% Premarket After Co's Epilepsy Implant Fails to Meet Main Efficacy Goal in Study

THOMSON REUTERS
·
27 May

Neuropace Inc - Study Meets 12-Week Post-Implant Safety Endpoint

THOMSON REUTERS
·
27 May

Neuropace Inc - Completes Primary Endpoint Analysis for Idiopathic Generalized Epilepsy Study

THOMSON REUTERS
·
27 May

Neuropace Inc: Reaffirms Its Previously Issued Full-Year 2025 Financial Guidance

THOMSON REUTERS
·
27 May

Neuropace - Primary Effectiveness Endpoint Not Statistically Significant in Overall Population

THOMSON REUTERS
·
27 May

Neuropace Inc - Preliminary Data Shows Favorable Seizure Reduction Rates for Rns System

THOMSON REUTERS
·
27 May

OrbiMed Advisors LLC Reports Disposal of Common Shares of NeuroPace Inc

Reuters
·
17 May

NeuroPace, Inc. Reports Strong Q1 2025 Earnings

TIPRANKS
·
16 May

NeuroPace Is Maintained at Overweight by JP Morgan

Dow Jones
·
15 May

NeuroPace Price Target Maintained With a $17.00/Share by Cantor Fitzgerald

Dow Jones
·
14 May

NeuroPace price target raised to $16 from $14 at JPMorgan

TIPRANKS
·
14 May

Neuropace Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
14 May

BRIEF-Neuropace, Inc. Q1 Revenue USD 22.524 Million Versus. IBES Estimate USD 21.8 Million

Reuters
·
14 May

NeuroPace Inc. Reports 24% Increase in Q1 2025 Revenue to $22.5M, Raises Full-Year Revenue Guidance to $93-$97M

Reuters
·
14 May

NeuroPace Q1 EPS $(0.21) Beats $(0.24) Estimate, Sales $22.52M Beat $21.85M Estimate

Benzinga
·
14 May

Neuropace, Inc. Q1 EPS USD -0.21 VS. Ibes Estimate USD -0.24

THOMSON REUTERS
·
14 May

NeuroPace (NPCE) Gets a Buy from Lake Street

TIPRANKS
·
12 May

Neuropace Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
10 May

NeuroPace’s Strong Market Position and Growth Potential Justify Buy Rating Amid Tariff Stability

TIPRANKS
·
16 Apr